The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors

CONCLUSION: Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.PMID:34510272 | DOI:10.1007/s00432-021-03781-6
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research